3i Group Acquires 51% Stake in French Nutrition Supplement Maker Laboratoire Nutergia

Why It Matters

The deal gives Nutergia private‑equity backing to scale its premium health‑supplement brand globally, while reinforcing 3i’s push into high‑growth consumer‑health assets.

Key Takeaways

• 3i acquires 51% of Nutergia for roughly €100‑150 million.
• Founder family retains significant minority stake and operational role.
• Nutergia aims to expand in Spain, Portugal, Belgium, Asia.
• Investment targets deeper market penetration, product innovation, digital channels.
• Nutergia has delivered double‑digit organic growth for over a decade.

Pulse Analysis

3i’s acquisition of a controlling stake in Laboratoire Nutergia reflects the private‑equity firm’s broader strategy to target differentiated consumer‑health businesses with strong brand equity. By committing an estimated $116‑$174 million, 3i positions itself to capitalize on the rising demand for scientifically backed nutrition products, a segment that has outperformed many traditional supplement categories in recent years. The investment aligns with 3i’s historical focus on companies that can leverage operational expertise to unlock cross‑border growth, especially in markets where health‑conscious spending is accelerating.

Nutergia, founded in 1989, has built a reputation for rigorous product development and a trusted presence in French pharmacies. Its Ergysport line caters to sports‑nutrition enthusiasts, while the core supplement portfolio serves a broader health‑care audience. The company’s double‑digit organic growth over more than a decade underscores its ability to scale without sacrificing quality. Exporting roughly a quarter of its volume to Europe and Asia, Nutergia already demonstrates a foothold in international markets, but its distribution remains heavily weighted toward traditional retail channels.

With 3i’s capital and strategic guidance, Nutergia is set to accelerate its expansion through several levers: deeper penetration of existing European markets, entry into new territories such as Portugal and broader Asia, and a push toward digital sales platforms that can capture younger, tech‑savvy consumers. Product innovation, particularly in premium, science‑driven formulations, will likely receive heightened investment, positioning Nutergia to compete with multinational players. The partnership illustrates how private equity can act as a catalyst for mid‑size health brands seeking to transition from regional leaders to global contenders.

Deal Summary

Private‑equity firm 3i Group has acquired a 51% majority stake in French sports‑nutrition and supplement maker Laboratoire Nutergia. The terms were not disclosed, though 3i indicated the investment likely falls between €100 million and €150 million ($116 million‑$174 million). The Lagarde family will retain a significant minority holding and remain active in the business.